ACADVL and metabolic disease: The confirmation of genetic and/or metabolic disorders occurred in 49 patients (21.4%), with VLCAD deficiency identified in 16 patients (7%) and an ELAC2 gene defect in ten patients (4.4%) (Tables 2 and 3).